Riccardo Bertolo1, Cristian Fiori1, Daniele Amparore1, Francesco Porpiglia2. 1. Division of Urology, Department of Oncology, School of Medicine, University of Turin-San Luigi Gonzaga Hospital, Regione Gonzole 10, 10043, Turin, Orbassano, Italy. 2. Division of Urology, Department of Oncology, School of Medicine, University of Turin-San Luigi Gonzaga Hospital, Regione Gonzole 10, 10043, Turin, Orbassano, Italy. porpiglia@libero.it.
Abstract
PURPOSE OF REVIEW: The purpose of the present systematic review is to offer a narrative synthesis of the available literature regarding the role of the temporary implantable nitinol device (TIND) (Medi-Tate®; Medi-Tate Ltd., Or Akiva, Israel) for the treatment of benign prostatic hyperplasia (BPH)-related lower urinary tract symptoms (LUTS), specifically focusing on the follow-up data. RECENT FINDINGS: Current available evidences are limited in this topic. Sample size of patients available for analysis is small. Moreover, the duration of follow-up period is intermediate and longer follow-up is required. At the available 3 years follow-up, the TIND implantation is safe, effective, and well tolerated. The extended follow-up of the first and only available cohort of patients who underwent TIND for LUTS related to BPH corroborated previous literature findings. Further studies are required in order to assess the durability of TIND outcomes over a longer follow-up, to better define the indications of this approach, and to demonstrate the advantages of second-generation device over the first.
PURPOSE OF REVIEW: The purpose of the present systematic review is to offer a narrative synthesis of the available literature regarding the role of the temporary implantable nitinol device (TIND) (Medi-Tate®; Medi-Tate Ltd., Or Akiva, Israel) for the treatment of benign prostatic hyperplasia (BPH)-related lower urinary tract symptoms (LUTS), specifically focusing on the follow-up data. RECENT FINDINGS: Current available evidences are limited in this topic. Sample size of patients available for analysis is small. Moreover, the duration of follow-up period is intermediate and longer follow-up is required. At the available 3 years follow-up, the TIND implantation is safe, effective, and well tolerated. The extended follow-up of the first and only available cohort of patients who underwent TIND for LUTS related to BPH corroborated previous literature findings. Further studies are required in order to assess the durability of TIND outcomes over a longer follow-up, to better define the indications of this approach, and to demonstrate the advantages of second-generation device over the first.
Entities:
Keywords:
Alternative therapies; BPH; LUTS; Minimally invasive; TIND
Authors: Stavros Gravas; Alexander Bachmann; Oliver Reich; Claus G Roehrborn; Peter J Gilling; Jean De La Rosette Journal: BJU Int Date: 2011-04 Impact factor: 5.588
Authors: Richard Naspro; Fernando Gomez Sancha; Michele Manica; Agostino Meneghini; Sascha Ahyai; Tevita Aho; Cristian Fiori; Ivano Vavassori; Luigi F DA Pozzo; Vito Pansadoro; Francesco Montorsi; Thomas R Herrmann Journal: Minerva Urol Nefrol Date: 2017-02-01 Impact factor: 3.720
Authors: Aldo Brassetti; Cosimo DE Nunzio; Nicolas B Delongchamps; Cristian Fiori; Francesco Porpiglia; Andrea Tubaro Journal: Minerva Urol Nefrol Date: 2016-12-01 Impact factor: 3.720
Authors: Sascha A Ahyai; Peter Gilling; Steven A Kaplan; Rainer M Kuntz; Stephan Madersbacher; Francesco Montorsi; Mark J Speakman; Christian G Stief Journal: Eur Urol Date: 2010-06-11 Impact factor: 20.096
Authors: Christian Gratzke; Alexander Bachmann; Aurelien Descazeaud; Marcus J Drake; Stephan Madersbacher; Charalampos Mamoulakis; Matthias Oelke; Kari A O Tikkinen; Stavros Gravas Journal: Eur Urol Date: 2015-01-19 Impact factor: 20.096
Authors: K M C Verhamme; J P Dieleman; G S Bleumink; J L H R Bosch; B H Ch Stricker; M C J M Sturkenboom Journal: Eur Urol Date: 2003-11 Impact factor: 20.096
Authors: P Grise; M Plante; J Palmer; J Martinez-Sagarra; C Hernandez; M Schettini; M Gonzalez-Martin; J Castiñeiras; P Ballanger; P Teillac; F Rolo; V Baena; J Erdmann; V Mirone Journal: Eur Urol Date: 2004-10 Impact factor: 20.096